RAY 121
Alternative Names: RAY-121Latest Information Update: 12 Dec 2024
At a glance
- Originator Chugai Pharmaceutical
- Class Monoclonal antibodies
- Mechanism of Action Complement C1s inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders; Immunological disorders
Most Recent Events
- 01 Dec 2024 Phase-I clinical trials in Immunological disorders in Turkey, Taiwan, Spain, Romania, Portugal, Poland, Norway, Netherlands, Italy, Hungary, Germany, France, Czech Republic, Croatia, Bulgaria, Austria, Australia (Parenteral) (NCT06723106)
- 14 Nov 2024 Efficacy, adverse event and pharmacokinetics data from phase Ia trial in Autoimmune disorders presented at the ACR Convergence 2024
- 12 Jun 2024 Phase-I clinical trials in Autoimmune disorders (In Volunteers) (IV) (EudraCT2024-515151-38-00)